PURPOSE: To evaluate vision-related quality of life in patients with chronic central serous chorioretinopathy (CSCR). DESIGN: Prospective, cross-sectional study. METHODS: The interviewer-administered National Eye Institute visual function questionnaire (NEI-VFQ-25) was used in 30 adult consecutive patients with chronic CSCR patients. The controls were 30 gender- and age-matched people with normal visual function who came from the same socioeconomic and educational background as the participants. RESULTS: Patients with CSCR had statistically significant lower scores than controls for all the subscales, except for general health. In the study group, all subscale scores of vision-related quality of life, except general health, showed statistically significant negative correlations with the visual acuity. CONCLUSIONS: People with CSCR have worse vision-related quality of life than people without the condition.
PURPOSE: To evaluate vision-related quality of life in patients with chronic central serous chorioretinopathy (CSCR). DESIGN: Prospective, cross-sectional study. METHODS: The interviewer-administered National Eye Institute visual function questionnaire (NEI-VFQ-25) was used in 30 adult consecutive patients with chronic CSCR patients. The controls were 30 gender- and age-matched people with normal visual function who came from the same socioeconomic and educational background as the participants. RESULTS:Patients with CSCR had statistically significant lower scores than controls for all the subscales, except for general health. In the study group, all subscale scores of vision-related quality of life, except general health, showed statistically significant negative correlations with the visual acuity. CONCLUSIONS:People with CSCR have worse vision-related quality of life than people without the condition.
Entities:
Keywords:
Central; NEI VFQ-25; chorioretinopathy; chronic; serous
Authors: Rajeev H Muni; Carolina L M Francisconi; Tina Felfeli; Michael Y K Mak; Alan R Berger; David T Wong; Filiberto Altomare; Louis R Giavedoni; Radha P Kohly; Peter J Kertes; Natalia Figueiredo; Fei Zuo; Kevin E Thorpe; Roxane J Hillier Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389